195 related articles for article (PubMed ID: 6677882)
1. Legal requirements for drug testing in children in Germany.
Hasskarl H
Pediatr Pharmacol (New York); 1983; 3(3-4):361-6. PubMed ID: 6677882
[TBL] [Abstract][Full Text] [Related]
2. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
3. Comparison of German and American law concerning clinical trials.
Deutsch E
Pediatr Pharmacol (New York); 1983; 3(3-4):353-9. PubMed ID: 6677881
[TBL] [Abstract][Full Text] [Related]
4. Legal aspects of clinical trials in Israel.
Frenkel DA
Isr J Med Sci; 1983 May; 19(5):452-7. PubMed ID: 6862852
[TBL] [Abstract][Full Text] [Related]
5. [Ethical and legal problems of medical responsibility in drug trials (author's transl)].
Nicolas F; Nicolas G
Anesth Analg (Paris); 1980; 37(9-10):605-6, 609-11. PubMed ID: 7469077
[TBL] [Abstract][Full Text] [Related]
6. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
8. [Legal liability and insurance questions regarding the testing of drugs, in particular with regard to the new drug law of 1976].
Granitza A
Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1978; 19():78-83. PubMed ID: 362173
[No Abstract] [Full Text] [Related]
9. [The rights of clinical research, especially in the area of psychiatry].
Deutsch E
Fortschr Neurol Psychiatr; 1996 Jan; 64(1):1-7. PubMed ID: 8850089
[TBL] [Abstract][Full Text] [Related]
10. [Juridical aspects of new treatment methods].
Krieger G
Z Hautkr; 1985 Aug; 60(16):1270-2, 1277-80, 1285-7. PubMed ID: 3901560
[TBL] [Abstract][Full Text] [Related]
11. [Human experimentation and criteria for obligatory medical care].
Staak M
MMW Munch Med Wochenschr; 1979 Apr; 121(15):513-6. PubMed ID: 108563
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic kits in parasitology: which controls?].
Rossi P
Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
[TBL] [Abstract][Full Text] [Related]
13. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
Box RJ; Spielmann H
Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
[TBL] [Abstract][Full Text] [Related]
14. [Clinical trials with minors in Germany--effects of the 12th amendment to the German Drug Code on the numbers of applications to Institutional Review Boards (IRB)].
Kölch M; Märsch C; Fegert JM; Lippert HD
Gesundheitswesen; 2009 Mar; 71(3):127-33. PubMed ID: 19221985
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy].
Ibáñez Sendín MD
Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375
[TBL] [Abstract][Full Text] [Related]
16. Development of medicines for children in Europe: ethical implications.
Saint Raymond A; Brasseur D
Paediatr Respir Rev; 2005 Mar; 6(1):45-51. PubMed ID: 15698816
[TBL] [Abstract][Full Text] [Related]
17. Drug trials in children: ethical, legal, and practical issues.
Kauffman RE
J Clin Pharmacol; 1994 Apr; 34(4):296-9. PubMed ID: 8006195
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies for use in man: current regulatory situation in the Federal Republic of Germany.
Haase M
Dev Biol Stand; 1990; 71():213-20. PubMed ID: 2205526
[TBL] [Abstract][Full Text] [Related]
19. [Differences between clinical trials according to the German law on pharmaceuticals (Arzneimittelgesetz) and trials according to the German law on medical products (Medizinproduktegesetz)].
Krummenauer F
Ophthalmologe; 2003 Feb; 100(2):150-4. PubMed ID: 12589461
[TBL] [Abstract][Full Text] [Related]
20. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].
Schnieders B
Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
